drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00398 | DB01320 | 79 | 651 | [
"DDInter1702",
"DDInter783"
] | Sorafenib | Fosphenytoin | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Moderate | 1 | [
[
[
79,
24,
651
]
],
[
[
79,
24,
307
],
[
307,
1,
651
]
],
[
[
79,
63,
362
],
[
362,
1,
651
]
],
[
[
79,
6,
6017
],
[
6017,
45,
... | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Modafinil"
],
[
... | Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil (Compound) resembles Fosphenytoin (Compound)
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Fosphenytoin (Compound)
So... |
DB00026 | DB14409 | 1,184 | 1,129 | [
"DDInter94",
"DDInter867"
] | Anakinra | Human adenovirus e serotype 4 strain cl-68578 antigen | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.... | Human adenovirus e serotype 4 strain cl-68578 antigen is a vaccine. | Moderate | 1 | [
[
[
1184,
24,
1129
]
],
[
[
1184,
64,
1057
],
[
1057,
24,
1129
]
],
[
[
1184,
24,
1683
],
[
1683,
24,
1129
]
],
[
[
1184,
63,
305
],
[
305... | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Anakinra",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eta... | Anakinra may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Anakinra may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB01229 | DB14443 | 973 | 987 | [
"DDInter1377",
"DDInter1931"
] | Paclitaxel | Vibrio cholerae CVD 103-HgR strain live antigen | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | _Vibrio cholerae_ CVD 103-HgR strain live antigen is a component of Vaxchora, an oral vaccine for immunization against _Vibrio cholerae_ serogroup O1. Cholera is an acute bacterial disease of the small intestine caused by _Vibrio cholerae_, which is gram-negative bacteria. Two serogroups of _V. cholerae_, O1 and O139, ... | Moderate | 1 | [
[
[
973,
24,
987
]
],
[
[
973,
24,
1480
],
[
1480,
24,
987
]
],
[
[
973,
63,
1488
],
[
1488,
24,
987
]
],
[
[
973,
64,
581
],
[
581,
... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}... | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Paclitaxel may cause a moderate interaction that could exacerbate diseases when... |
DB08815 | DB09065 | 154 | 760 | [
"DDInter1104",
"DDInter424"
] | Lurasidone | Cobicistat | Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Major | 2 | [
[
[
154,
25,
760
]
],
[
[
154,
63,
1101
],
[
1101,
23,
760
]
],
[
[
154,
64,
723
],
[
723,
24,
760
]
],
[
[
154,
24,
868
],
[
868,
2... | [
[
[
"Lurasidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
]
],
[
[
"Lurasidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene... | Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Lurasidone may lead to a major life threatening interaction when taken with Aprepitant and Aprepitant may cause a ... |
DB00945 | DB06209 | 1,479 | 256 | [
"DDInter20",
"DDInter1508"
] | Acetylsalicylic acid | Prasugrel | Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial... | Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversib... | Moderate | 1 | [
[
[
1479,
24,
256
]
],
[
[
1479,
6,
10215
],
[
10215,
45,
256
]
],
[
[
1479,
21,
28681
],
[
28681,
60,
256
]
],
[
[
1479,
23,
944
],
[
944... | [
[
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prasugrel"
]
],
[
[
"Acetylsalicylic acid",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is boun... | Acetylsalicylic acid (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Prasugrel (Compound)
Acetylsalicylic acid (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Prasugrel (Compound)
Acetylsalicylic acid may cause a minor interaction that can limit clinical e... |
DB01276 | DB01319 | 123 | 34 | [
"DDInter706",
"DDInter777"
] | Exenatide | Fosamprenavir | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease. | Moderate | 1 | [
[
[
123,
24,
34
]
],
[
[
123,
63,
1091
],
[
1091,
40,
34
]
],
[
[
123,
63,
609
],
[
609,
23,
34
]
],
[
[
123,
63,
1144
],
[
1144,
24... | [
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosamprenavir"
]
],
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amprenavir"
],
[
... | Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Amprenavir and Amprenavir (Compound) resembles Fosamprenavir (Compound)
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a minor interaction that... |
DB04946 | DB06699 | 924 | 774 | [
"DDInter907",
"DDInter493"
] | Iloperidone | Degarelix | Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. O... | Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH... | Major | 2 | [
[
[
924,
25,
774
]
],
[
[
924,
64,
521
],
[
521,
1,
774
]
],
[
[
924,
21,
29177
],
[
29177,
60,
774
]
],
[
[
924,
62,
112
],
[
112,
... | [
[
[
"Iloperidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Degarelix"
]
],
[
[
"Iloperidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Goserelin"
],
[
"Goserelin",
"{u} (C... | Iloperidone may lead to a major life threatening interaction when taken with Goserelin and Goserelin (Compound) resembles Degarelix (Compound)
Iloperidone (Compound) causes Musculoskeletal stiffness (Side Effect) and Musculoskeletal stiffness (Side Effect) is caused by Degarelix (Compound)
Iloperidone may cause a minor... |
DB00352 | DB08868 | 482 | 1,011 | [
"DDInter1814",
"DDInter737"
] | Tioguanine | Fingolimod | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Major | 2 | [
[
[
482,
25,
1011
]
],
[
[
482,
24,
1247
],
[
1247,
23,
1011
]
],
[
[
482,
24,
242
],
[
242,
63,
1011
]
],
[
[
482,
24,
1136
],
[
1136,
... | [
[
[
"Tioguanine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulf... | Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Fingolimod
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir ... |
DB00011 | DB01004 | 1,451 | 563 | [
"DDInter944",
"DDInter806"
] | Interferon alfa-n1 | Ganciclovir | Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes. | An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections. | Moderate | 1 | [
[
[
1451,
24,
563
]
],
[
[
1451,
24,
248
],
[
248,
40,
563
]
],
[
[
1451,
24,
36
],
[
36,
63,
563
]
],
[
[
1451,
25,
1101
],
[
1101,
... | [
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valgancicl... | Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir and Valganciclovir (Compound) resembles Ganciclovir (Compound)
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Eribulin and Eribulin may cause a moderate i... |
DB01244 | DB05239 | 762 | 866 | [
"DDInter192",
"DDInter425"
] | Bepridil | Cobimetinib | A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. It is no longer marketed in the United St... | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment ... | Moderate | 1 | [
[
[
762,
24,
866
]
],
[
[
762,
64,
888
],
[
888,
24,
866
]
],
[
[
762,
24,
1478
],
[
1478,
63,
866
]
],
[
[
762,
25,
484
],
[
484,
6... | [
[
[
"Bepridil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobimetinib"
]
],
[
[
"Bepridil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
... | Bepridil may lead to a major life threatening interaction when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Bepridil may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moder... |
DB00039 | DB06704 | 1,253 | 247 | [
"DDInter1380",
"DDInter952"
] | Palifermin | Iobenguane (I-131) | Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004. | 2-[(3-iodophenyl)methyl]guanidine is an organoiodine compound. | Moderate | 1 | [
[
[
1253,
24,
247
]
],
[
[
1253,
24,
1077
],
[
1077,
24,
1136
],
[
1136,
24,
247
]
],
[
[
1253,
24,
1488
],
[
1488,
21,
28703
],
[
28703,
... | [
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iobenguane"
]
],
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belinostat"
],
[
... | Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Belinostat and Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Denosumab and Denosum... |
DB09330 | DB11828 | 985 | 1,406 | [
"DDInter1352",
"DDInter1281"
] | Osimertinib | Neratinib | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer. | Moderate | 1 | [
[
[
985,
24,
1406
]
],
[
[
985,
64,
392
],
[
392,
24,
1406
]
],
[
[
985,
24,
710
],
[
710,
63,
1406
]
],
[
[
985,
24,
119
],
[
119,
... | [
[
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Osimertinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lapatinib"
],
[
"Lapatinib"... | Osimertinib may lead to a major life threatening interaction when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib and Binimetinib may cause... |
DB09074 | DB12674 | 1,362 | 975 | [
"DDInter1327",
"DDInter1105"
] | Olaparib | Lurbinectedin | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Lurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma, chronic lymphocytic leukemia (CLL), breast cancer, and small-cell lung cancer (SCLC). It is a derivative of the marine-derived agent ecteinascidin ([trabectedin]), an anticancer agent fou... | Moderate | 1 | [
[
[
1362,
24,
975
]
],
[
[
1362,
63,
1488
],
[
1488,
24,
975
]
],
[
[
1362,
24,
159
],
[
159,
63,
975
]
],
[
[
1362,
24,
98
],
[
98,
... | [
[
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurbinectedin"
]
],
[
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludarabine"
],
[
... | Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine and Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and La... |
DB00758 | DB09272 | 1,347 | 412 | [
"DDInter413",
"DDInter632"
] | Clopidogrel | Eluxadoline | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recen... | Eluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). The mu-, kappa-, and delta-opioid receptors mediate endogenous and exogenous opioid response in the central nervous system ... | Moderate | 1 | [
[
[
1347,
24,
412
]
],
[
[
1347,
24,
700
],
[
700,
24,
412
]
],
[
[
1347,
63,
441
],
[
441,
24,
412
]
],
[
[
1347,
25,
543
],
[
543,
... | [
[
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atorvastatin"
],
... | Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Atorvastatin and Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Delavirdine an... |
DB00748 | DB11642 | 662 | 938 | [
"DDInter297",
"DDInter1480"
] | Carbinoxamine | Pitolisant | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnag... | Moderate | 1 | [
[
[
662,
24,
938
]
],
[
[
662,
1,
28
],
[
28,
24,
938
]
],
[
[
662,
63,
1233
],
[
1233,
24,
938
]
],
[
[
662,
24,
820
],
[
820,
24,
... | [
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Carbinoxamine",
"{u} (Compound) resembles {v} (Compound)",
"Bisacodyl"
],
[
"Bisacodyl",
"{u} may cause a mod... | Carbinoxamine (Compound) resembles Bisacodyl (Compound) and Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Triprolidine and Triprolidine may cause a moderate interaction th... |
DB00459 | DB00759 | 640 | 1,620 | [
"DDInter21",
"DDInter1783"
] | Acitretin | Tetracycline | An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of etretinate with the advantage of a much shorter half-life when compared with etretinate. | Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some e... | Major | 2 | [
[
[
640,
25,
1620
]
],
[
[
640,
25,
1572
],
[
1572,
40,
1620
]
],
[
[
640,
64,
964
],
[
964,
40,
1620
]
],
[
[
640,
6,
1829
],
[
1829,
... | [
[
[
"Acitretin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tetracycline"
]
],
[
[
"Acitretin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Demeclocycline"
],
[
"Demeclocycline",
... | Acitretin may lead to a major life threatening interaction when taken with Demeclocycline and Demeclocycline (Compound) resembles Tetracycline (Compound)
Acitretin may lead to a major life threatening interaction when taken with Doxycycline and Doxycycline (Compound) resembles Tetracycline (Compound)
Acitretin (Compoun... |
DB01156 | DB12015 | 593 | 1,033 | [
"DDInter252",
"DDInter53"
] | Bupropion | Alpelisib | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metaboli... | Moderate | 1 | [
[
[
593,
24,
1033
]
],
[
[
593,
25,
154
],
[
154,
24,
1033
]
],
[
[
593,
64,
576
],
[
576,
24,
1033
]
],
[
[
593,
63,
772
],
[
772,
... | [
[
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lurasidone"
],
[
"Lurasidone",
... | Bupropion may lead to a major life threatening interaction when taken with Lurasidone and Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Bupropion may lead to a major life threatening interaction when taken with Methadone and Methadone may cause a moderate interacti... |
DB00382 | DB09330 | 62 | 985 | [
"DDInter1734",
"DDInter1352"
] | Tacrine | Osimertinib | A centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders. Tacrine has been discontinued for the United States market. | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Moderate | 1 | [
[
[
62,
24,
985
]
],
[
[
62,
24,
112
],
[
112,
23,
985
]
],
[
[
62,
24,
663
],
[
663,
24,
985
]
],
[
[
62,
24,
1383
],
[
1383,
63,
... | [
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
... | Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Metho... |
DB00701 | DB13928 | 1,091 | 1,385 | [
"DDInter90",
"DDInter1660"
] | Amprenavir | Semaglutide | Amprenavir is a protease inhibitor used to treat HIV infection. | Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. Semaglutide was developed by Novo Nordisk and approved ... | Moderate | 1 | [
[
[
1091,
24,
1385
]
],
[
[
1091,
24,
891
],
[
891,
24,
1385
]
],
[
[
1091,
25,
1476
],
[
1476,
24,
1385
]
],
[
[
1091,
40,
34
],
[
34,
... | [
[
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
],
[... | Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Amprenavir may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may c... |
DB00557 | DB08897 | 252 | 1,429 | [
"DDInter895",
"DDInter22"
] | Hydroxyzine | Aclidinium | Hydroxyzine is a first-generation histamine H<sub>1</sub>-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955, and has since remained a relatively common treatment for allergic conditions such as p... | Aclidinium is an anticholinergic for the long-term management of chronic obstructive pulmonary disease (COPD). It has a much higher propensity to bind to muscarinic receptors than nicotinic receptors. FDA approved on July 24, 2012. | Moderate | 1 | [
[
[
252,
24,
1429
]
],
[
[
252,
63,
352
],
[
352,
24,
1429
]
],
[
[
252,
24,
1511
],
[
1511,
24,
1429
]
],
[
[
252,
21,
28779
],
[
28779,
... | [
[
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aclidinium"
]
],
[
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trospium"
],
[
... | Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Aclidinium
Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzo... |
DB01182 | DB08871 | 371 | 36 | [
"DDInter1534",
"DDInter666"
] | Propafenone | Eribulin | An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated. | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Moderate | 1 | [
[
[
371,
24,
36
]
],
[
[
371,
63,
1424
],
[
1424,
24,
36
]
],
[
[
371,
24,
820
],
[
820,
24,
36
]
],
[
[
371,
24,
28
],
[
28,
63,
... | [
[
[
"Propafenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Propafenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
],
[
... | Propafenone may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Propafenone may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine... |
DB00889 | DB04953 | 1,133 | 495 | [
"DDInter840",
"DDInter708"
] | Granisetron | Ezogabine | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients wi... | Moderate | 1 | [
[
[
1133,
24,
495
]
],
[
[
1133,
21,
28997
],
[
28997,
60,
495
]
],
[
[
1133,
23,
112
],
[
112,
23,
495
]
],
[
[
1133,
24,
1148
],
[
1148,... | [
[
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ezogabine"
]
],
[
[
"Granisetron",
"{u} (Compound) causes {v} (Side Effect)",
"Ill-defined disorder"
],
[
"Ill-defined disorder",
"{u... | Granisetron (Compound) causes Ill-defined disorder (Side Effect) and Ill-defined disorder (Side Effect) is caused by Ezogabine (Compound)
Granisetron may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effect... |
DB11689 | DB12364 | 321 | 1,421 | [
"DDInter1659",
"DDInter200"
] | Selumetinib | Betrixaban | Activation of the Raf-MEK-ERK signalling pathway is known to be implemented in several types of malignancies; thus, mitogen-activated protein kinase kinase (MEK) inhibitors such as selumetinib are important tools that can target the problematic overactivity of this pathway. Results from clinical trials investigating ea... | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals ... | Moderate | 1 | [
[
[
321,
24,
1421
]
],
[
[
321,
25,
1017
],
[
1017,
24,
1421
]
],
[
[
321,
24,
1476
],
[
1476,
24,
1421
]
],
[
[
321,
64,
760
],
[
760,
... | [
[
[
"Selumetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Selumetinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
],
[
"Lorlatin... | Selumetinib may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Selumetinib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may caus... |
DB08901 | DB09280 | 1,468 | 1,604 | [
"DDInter1492",
"DDInter1101"
] | Ponatinib | Lumacaftor | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Con... | Moderate | 1 | [
[
[
1468,
24,
1604
]
],
[
[
1468,
24,
1060
],
[
1060,
62,
1604
]
],
[
[
1468,
64,
1171
],
[
1171,
24,
1604
]
],
[
[
1468,
62,
379
],
[
379... | [
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumacaftor"
]
],
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
],
... | Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin and Enfortumab vedotin may cause a minor interaction that can limit clinical effects when taken with Lumacaftor
Ponatinib may lead to a major life threatening interaction when taken with Meloxicam and Meloxicam ... |
DB00041 | DB00264 | 1,648 | 88 | [
"DDInter38",
"DDInter1200"
] | Aldesleukin | Metoprolol | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | Metoprolol is a selective beta-1 blocker commonly employed as the succinate and tartrate derivatives depending if the formulation is designed to be of immediate release or extended release.[A175159, L5530] The possibility of the generation of these formulations comes from the lower systemic bioavailability of the succi... | Moderate | 1 | [
[
[
1648,
24,
88
]
],
[
[
1648,
24,
1121
],
[
1121,
1,
88
]
],
[
[
1648,
24,
819
],
[
819,
40,
88
]
],
[
[
1648,
24,
849
],
[
849,
6... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoprolol"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisoprolol"
],
[
... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Bisoprolol and Bisoprolol (Compound) resembles Metoprolol (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Acebutolol and Acebutolol (Compound) resembles Metoprolol (Compound... |
DB00059 | DB00263 | 1,560 | 1,029 | [
"DDInter1404",
"DDInter1727"
] | Pegaspargase | Sulfisoxazole | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms. | Moderate | 1 | [
[
[
1560,
24,
1029
]
],
[
[
1560,
24,
1247
],
[
1247,
40,
1029
]
],
[
[
1560,
24,
161
],
[
161,
1,
1029
]
],
[
[
1560,
24,
245
],
[
245,
... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfisoxazole"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfamethoxazole"
... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole (Compound) resembles Sulfisoxazole (Compound)
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Sulfadiazine and Sulfadiazine (Compound) resembles... |
DB00850 | DB09038 | 1,630 | 1,450 | [
"DDInter1432",
"DDInter636"
] | Perphenazine | Empagliflozin | An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
1630,
24,
1450
]
],
[
[
1630,
63,
485
],
[
485,
24,
1450
]
],
[
[
1630,
24,
659
],
[
659,
63,
1450
]
],
[
[
1630,
24,
688
],
[
688,
... | [
[
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
],
... | Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol a... |
DB00790 | DB01067 | 664 | 959 | [
"DDInter1431",
"DDInter826"
] | Perindopril | Glipizide | Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible fo... | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Moderate | 1 | [
[
[
664,
24,
959
]
],
[
[
664,
63,
245
],
[
245,
40,
959
]
],
[
[
664,
24,
1411
],
[
1411,
1,
959
]
],
[
[
664,
21,
29442
],
[
29442,
... | [
[
[
"Perindopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Perindopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
... | Perindopril may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Perindopril may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Glipizide (Compou... |
DB00264 | DB09564 | 88 | 1,296 | [
"DDInter1200",
"DDInter930"
] | Metoprolol | Insulin degludec | Metoprolol is a selective beta-1 blocker commonly employed as the succinate and tartrate derivatives depending if the formulation is designed to be of immediate release or extended release.[A175159, L5530] The possibility of the generation of these formulations comes from the lower systemic bioavailability of the succi... | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
88,
24,
1296
]
],
[
[
88,
40,
17
],
[
17,
24,
1296
]
],
[
[
88,
24,
1411
],
[
1411,
24,
1296
]
],
[
[
88,
23,
542
],
[
542,
24,
... | [
[
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Metoprolol",
"{u} (Compound) resembles {v} (Compound)",
"Sotalol"
],
[
"Sotalol",
"{u} may cause a moderat... | Metoprolol (Compound) resembles Sotalol (Compound) and Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that cou... |
DB01114 | DB08893 | 272 | 271 | [
"DDInter362",
"DDInter1229"
] | Chlorpheniramine | Mirabegron | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Mirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. It is unique amongst overactive bladder treatment options in that, unlike other treatments such as [solifenacin] and [darifenacin], it lacks significa... | Moderate | 1 | [
[
[
272,
24,
271
]
],
[
[
272,
6,
8374
],
[
8374,
45,
271
]
],
[
[
272,
21,
28956
],
[
28956,
60,
271
]
],
[
[
272,
24,
283
],
[
283,
... | [
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mirabegron"
]
],
[
[
"Chlorpheniramine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} ... | Chlorpheniramine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Mirabegron (Compound)
Chlorpheniramine (Compound) causes Palpitations (Side Effect) and Palpitations (Side Effect) is caused by Mirabegron (Compound)
Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken ... |
DB00532 | DB04865 | 208 | 4 | [
"DDInter1152",
"DDInter1335"
] | Mephenytoin | Omacetaxine mepesuccinate | Mephenytoin is used for the treatment of refractory partial epilepsy. Mephenytoin is a solid. This compound belongs to the phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. Mephenytoin is known to target sodium channel protein type 5 subuni... | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Moderate | 1 | [
[
[
208,
24,
4
]
],
[
[
208,
24,
770
],
[
770,
24,
4
]
],
[
[
208,
63,
589
],
[
589,
24,
4
]
],
[
[
208,
24,
259
],
[
259,
63,
... | [
[
[
"Mephenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Mephenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomid... | Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Ci... |
DB01364 | DB13139 | 22 | 1,032 | [
"DDInter650",
"DDInter1063"
] | Ephedrine | Levosalbutamol | Ephedrine was first described in western literature in 1888, as a naturally occurring component of the ephedra plant, along with [pseudoephedrine]. Ephedrine acts as both a direct and indirect sympathomimetic. It is an alpha- and beta-adrenergic receptor agonist; however, it also causes the indirect release of norepine... | Levosalbutamol, or levalbuterol, is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). [Salbutamol] has been marketed as a racemic mixture, although beta2-agonist activity resides almost exclusively in the (R)-enantiomer. The enantioselective ... | Moderate | 1 | [
[
[
22,
24,
1032
]
],
[
[
22,
62,
1220
],
[
1220,
23,
1032
]
],
[
[
22,
74,
73
],
[
73,
24,
1032
]
],
[
[
22,
63,
1048
],
[
1048,
24... | [
[
[
"Ephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levosalbutamol"
]
],
[
[
"Ephedrine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexamethasone"
],
[... | Ephedrine may cause a minor interaction that can limit clinical effects when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Levosalbutamol
Ephedrine (Compound) resembles Phentermine (Compound) and Ephedrine may cause a moderate interaction that c... |
DB01276 | DB09381 | 123 | 192 | [
"DDInter706",
"DDInter678"
] | Exenatide | Esterified estrogens | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Esterified estrogens contain a mixture of estrogenic substances; the principle component is estrone. Preparations contain 75% to 85% sodium estrone sulfate and 6% to 15% sodium equilin sulfate such that the total is not <90%. Esterified estrogens are a man-made mixture of estrogens that are used to treat symptoms of me... | Moderate | 1 | [
[
[
123,
24,
192
]
],
[
[
123,
24,
1019
],
[
1019,
63,
192
]
],
[
[
123,
63,
1685
],
[
1685,
24,
192
]
],
[
[
123,
24,
1040
],
[
1040,
... | [
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esterified estrogens"
]
],
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
],... | Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Esterified estrogens
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Insulin hum... |
DB00581 | DB06589 | 355 | 1,250 | [
"DDInter1018",
"DDInter1400"
] | Lactulose | Pazopanib | Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L6199,L6202] Despite being first synthesized in 1929, investigations regarding its p... | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Moderate | 1 | [
[
[
355,
24,
1250
]
],
[
[
355,
21,
28658
],
[
28658,
60,
1250
]
],
[
[
355,
24,
1630
],
[
1630,
24,
1250
]
],
[
[
355,
24,
28
],
[
28,
... | [
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Lactulose",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caused by... | Lactulose (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Pazopanib (Compound)
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine and Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Pazopani... |
DB00705 | DB08875 | 441 | 1,618 | [
"DDInter496",
"DDInter262"
] | Delavirdine | Cabozantinib | A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Major | 2 | [
[
[
441,
25,
1618
]
],
[
[
441,
25,
1135
],
[
1135,
62,
1618
]
],
[
[
441,
63,
723
],
[
723,
24,
1618
]
],
[
[
441,
24,
384
],
[
384,
... | [
[
[
"Delavirdine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Delavirdine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u}... | Delavirdine may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause ... |
DB00963 | DB01225 | 1,263 | 500 | [
"DDInter241",
"DDInter645"
] | Bromfenac | Enoxaparin | Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Ophthalmic NSAIDs are becoming a cornerstone for the management of ocular pain and inflammation. Their well-characterized anti-inflammatory activity, analgesic property, and established safety record have also made NSAIDs an important tool f... | Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the inc... | Major | 2 | [
[
[
1263,
25,
500
]
],
[
[
1263,
21,
28719
],
[
28719,
60,
500
]
],
[
[
1263,
63,
305
],
[
305,
24,
500
]
],
[
[
1263,
24,
222
],
[
222,
... | [
[
[
"Bromfenac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enoxaparin"
]
],
[
[
"Bromfenac",
"{u} (Compound) causes {v} (Side Effect)",
"Pain"
],
[
"Pain",
"{u} (Side Effect) is caused by {v} (Compound)",
... | Bromfenac (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Enoxaparin (Compound)
Bromfenac may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseas... |
DB00877 | DB06595 | 629 | 1,491 | [
"DDInter1678",
"DDInter1214"
] | Sirolimus | Midostaurin | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Moderate | 1 | [
[
[
629,
24,
1491
]
],
[
[
629,
24,
761
],
[
761,
24,
1491
]
],
[
[
629,
63,
888
],
[
888,
24,
1491
]
],
[
[
629,
24,
1017
],
[
1017,
... | [
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
],
[
... | Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxi... |
DB01087 | DB11837 | 1,520 | 1,297 | [
"DDInter1520",
"DDInter1351"
] | Primaquine | Osilodrostat | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Ad... | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Moderate | 1 | [
[
[
1520,
24,
1297
]
],
[
[
1520,
62,
112
],
[
112,
23,
1297
]
],
[
[
1520,
24,
623
],
[
623,
24,
1297
]
],
[
[
1520,
63,
401
],
[
401,
... | [
[
[
"Primaquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Primaquine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[... | Primaquine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Primaquine may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine and Qu... |
DB00762 | DB00812 | 613 | 998 | [
"DDInter973",
"DDInter1451"
] | Irinotecan | Phenylbutazone | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cel... | A drug that has anti-inflammatory, antipyretic, and analgesic activities. It is especially effective in the treatment of ankylosing spondylitis. It also is useful in rheumatoid arthritis and Reiter's syndrome (investigational indication). Although phenylbutazone is effective in gouty arthritis, risk/benefit conside... | Moderate | 1 | [
[
[
613,
24,
998
]
],
[
[
613,
24,
804
],
[
804,
40,
998
]
],
[
[
613,
63,
307
],
[
307,
1,
998
]
],
[
[
613,
64,
362
],
[
362,
1,
... | [
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylbutazone"
]
],
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfinpyrazone"
],
... | Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Sulfinpyrazone and Sulfinpyrazone (Compound) resembles Phenylbutazone (Compound)
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil (Compound) resembles Phenylbutazo... |
DB01229 | DB09121 | 973 | 1,328 | [
"DDInter1377",
"DDInter140"
] | Paclitaxel | Aurothioglucose | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Aurothioglucose, also known as gold thioglucose, was formerly used to treat rheumatoid arthritis. Contemporary research on the effect of gold salts treatment began in 1935, primarily to reduce inflammation and to slow disease progression in patients with rheumatoid arthritis . The use of gold compounds has decreased si... | Moderate | 1 | [
[
[
973,
24,
1328
]
],
[
[
973,
63,
367
],
[
367,
24,
1328
]
],
[
[
973,
64,
581
],
[
581,
24,
1328
]
],
[
[
973,
24,
310
],
[
310,
... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aurothioglucose"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon alfacon-1"
... | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Interferon alfacon-1 and Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Aurothioglucose
Paclitaxel may lead to a major life threatening interaction when taken with Infliximab ... |
DB01255 | DB11978 | 633 | 124 | [
"DDInter1078",
"DDInter822"
] | Lisdexamfetamine | Glasdegib | Lisdexamfetamine is a prodrug of [dextroamphetamine], a central nervous system stimulant known as d-amphetamine, covalently attached to the naturally occurring amino acid L-lysine. Lisdexamfetamine is the first chemically formulated prodrug stimulant and was first approved by the FDA in April 2008. It was also approved... | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Moderate | 1 | [
[
[
633,
24,
124
]
],
[
[
633,
62,
112
],
[
112,
23,
124
]
],
[
[
633,
63,
79
],
[
79,
24,
124
]
],
[
[
633,
24,
1342
],
[
1342,
24,... | [
[
[
"Lisdexamfetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Lisdexamfetamine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
... | Lisdexamfetamine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Lisdexamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Sorafeni... |
DB06151 | DB09278 | 531 | 852 | [
"DDInter19",
"DDInter24"
] | Acetylcysteine | Activated charcoal | Acetylcysteine is an antioxidant and glutathione inducer indicated for mucolytic therapy and the treatment of [acetaminophen] overdose.[L31378,L31383,L31388,L31478] Acetylcysteine has also been studied for a wide variety of off-label indications with mixed results.[A228158,A228163,A228168] Acetylcysteine was granted FD... | Activated charcoal, or activated carbon, is an amorphous form of carbon prepared from incomplete combustion of carbonaceous organic matter. It is activated by an oxidizing gas flow at high temperature passed over its surface to make a fine network of pores, producing a material with large surface area and high affinity... | Minor | 0 | [
[
[
531,
23,
852
]
],
[
[
531,
21,
28644
],
[
28644,
60,
21
],
[
21,
24,
852
]
],
[
[
531,
21,
28868
],
[
28868,
60,
1096
],
[
1096,
25,... | [
[
[
"Acetylcysteine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Activated charcoal"
]
],
[
[
"Acetylcysteine",
"{u} (Compound) causes {v} (Side Effect)",
"Syncope"
],
[
"Syncope",
"{u} (Side Effec... | Acetylcysteine (Compound) causes Syncope (Side Effect) and Syncope (Side Effect) is caused by Amitriptyline (Compound) and Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Activated charcoal
Acetylcysteine (Compound) causes Stomatitis (Side Effect) and Stomatitis (Side Effec... |
DB01173 | DB08897 | 358 | 1,429 | [
"DDInter1349",
"DDInter22"
] | Orphenadrine | Aclidinium | A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm. | Aclidinium is an anticholinergic for the long-term management of chronic obstructive pulmonary disease (COPD). It has a much higher propensity to bind to muscarinic receptors than nicotinic receptors. FDA approved on July 24, 2012. | Moderate | 1 | [
[
[
358,
24,
1429
]
],
[
[
358,
63,
352
],
[
352,
24,
1429
]
],
[
[
358,
24,
1511
],
[
1511,
24,
1429
]
],
[
[
358,
6,
4304
],
[
4304,
... | [
[
[
"Orphenadrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aclidinium"
]
],
[
[
"Orphenadrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trospium"
],
[
... | Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Aclidinium
Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepen... |
DB08827 | DB14723 | 990 | 159 | [
"DDInter1085",
"DDInter1026"
] | Lomitapide | Larotrectinib | Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R). | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Major | 2 | [
[
[
990,
25,
159
]
],
[
[
990,
23,
1135
],
[
1135,
23,
159
]
],
[
[
990,
24,
98
],
[
98,
24,
159
]
],
[
[
990,
64,
597
],
[
597,
24,... | [
[
[
"Lomitapide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Larotrectinib"
]
],
[
[
"Lomitapide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol"... | Lomitapide may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Lomitapide may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem ma... |
DB09268 | DB13074 | 1,662 | 877 | [
"DDInter1464",
"DDInter1110"
] | Picosulfuric acid | Macimorelin | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Moderate | 1 | [
[
[
1662,
24,
877
]
],
[
[
1662,
63,
112
],
[
112,
23,
877
]
],
[
[
1662,
63,
1479
],
[
1479,
24,
877
]
],
[
[
1662,
24,
913
],
[
913,
... | [
[
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazol... | Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Ac... |
DB00001 | DB00749 | 1,578 | 59 | [
"DDInter1037",
"DDInter699"
] | Lepirudin | Etodolac | Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor.[L41539,L41569] Natural hirudin is an endogenous anticoagulant found in _Hirudo medicinalis_ leeches. Lepirudin is produced in yeast cells and is identical to natural hirudin except for the absence o... | Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. | Moderate | 1 | [
[
[
1578,
24,
59
]
],
[
[
1578,
25,
25
],
[
25,
24,
59
]
],
[
[
1578,
24,
1039
],
[
1039,
63,
59
]
],
[
[
1578,
25,
1046
],
[
1046,
... | [
[
[
"Lepirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etodolac"
]
],
[
[
"Lepirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anistreplase"
],
[
"Anistreplase... | Lepirudin may lead to a major life threatening interaction when taken with Anistreplase and Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Etodolac
Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine ... |
DB00903 | DB01088 | 1,680 | 714 | [
"DDInter686",
"DDInter908"
] | Etacrynic acid | Iloprost | A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as ... | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | Moderate | 1 | [
[
[
1680,
24,
714
]
],
[
[
1680,
23,
1479
],
[
1479,
24,
714
]
],
[
[
1680,
63,
1648
],
[
1648,
24,
714
]
],
[
[
1680,
24,
1450
],
[
1450,... | [
[
[
"Etacrynic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
]
],
[
[
"Etacrynic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Acetylsalicylic acid"
... | Etacrynic acid may cause a minor interaction that can limit clinical effects when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Iloprost
Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB00295 | DB00810 | 475 | 456 | [
"DDInter1244",
"DDInter211"
] | Morphine | Biperiden | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | A muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine. | Moderate | 1 | [
[
[
475,
24,
456
]
],
[
[
475,
24,
1105
],
[
1105,
40,
456
]
],
[
[
475,
6,
4973
],
[
4973,
45,
456
]
],
[
[
475,
24,
104
],
[
104,
... | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Biperiden"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trihexyphenidyl"
],
[
... | Morphine may cause a moderate interaction that could exacerbate diseases when taken with Trihexyphenidyl and Trihexyphenidyl (Compound) resembles Biperiden (Compound)
Morphine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Biperiden (Compound)
Morphine may cause a moderate interaction that could exacerbate ... |
DB01577 | DB09154 | 1,529 | 1,475 | [
"DDInter1161",
"DDInter1686"
] | Metamfetamine | Sodium citrate | Metamfetamine (methamphetamine) is a psychostimulant and sympathomimetic drug, and a member of the amphetamine group of sympathomimetic amines. Methamphetamine can induce effects such as euphoria, increased alertness and energy, and enhanced self-esteem. It is a scheduled drug in most countries due to its high potentia... | Sodium citrate is the sodium salt of citric acid. It is white, crystalline powder or white, granular crystals, slightly deliquescent in moist air, freely soluble in water, practically insoluble in alcohol. Like citric acid, it has a sour taste. From the medical point of view, it is used as alkalinizing agent. It works ... | Moderate | 1 | [
[
[
1529,
24,
1475
]
],
[
[
1529,
63,
1411
],
[
1411,
23,
1475
]
],
[
[
1529,
63,
22
],
[
22,
24,
1475
]
],
[
[
1529,
24,
478
],
[
478,
... | [
[
[
"Metamfetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium citrate"
]
],
[
[
"Metamfetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
... | Metamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a minor interaction that can limit clinical effects when taken with Sodium citrate
Metamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine a... |
DB00176 | DB01124 | 529 | 1,411 | [
"DDInter770",
"DDInter1828"
] | Fluvoxamine | Tolbutamide | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Moderate | 1 | [
[
[
529,
24,
1411
]
],
[
[
529,
24,
959
],
[
959,
40,
1411
]
],
[
[
529,
6,
10215
],
[
10215,
45,
1411
]
],
[
[
529,
21,
29222
],
[
29222,... | [
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
... | Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Fluvoxamine (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Tolbutamide (Compound)
Fluvoxamine (Compound) causes Hypoglycaemia (Side Effect) and ... |
DB00467 | DB00694 | 1,467 | 51 | [
"DDInter644",
"DDInter485"
] | Enoxacin | Daunorubicin | A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid. | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Minor | 0 | [
[
[
1467,
23,
51
]
],
[
[
1467,
6,
7950
],
[
7950,
45,
51
]
],
[
[
1467,
7,
10439
],
[
10439,
46,
51
]
],
[
[
1467,
7,
5178
],
[
5178,
... | [
[
[
"Enoxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Daunorubicin"
]
],
[
[
"Enoxacin",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
... | Enoxacin (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Daunorubicin (Compound)
Enoxacin (Compound) upregulates PROS1 (Gene) and PROS1 (Gene) is upregulated by Daunorubicin (Compound)
Enoxacin (Compound) upregulates XBP1 (Gene) and XBP1 (Gene) is downregulated by Daunorubicin (Compound)
Enoxacin (Compound... |
DB00814 | DB13620 | 1,171 | 948 | [
"DDInter1143",
"DDInter1499"
] | Meloxicam | Potassium gluconate | Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis. With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing. Meloxicam is ... | Potassium gluconate is a salt of and is classified as a food additive by the FDA . It is also used as a potassium supplement . Potassium is an essential nutrient. It is the most abundant cation in the intracellular fluid, where it plays a key role in maintaining cell function . In dietary supplements, potassium is ofte... | Moderate | 1 | [
[
[
1171,
24,
948
]
],
[
[
1171,
24,
848
],
[
848,
24,
948
]
],
[
[
1171,
1,
1027
],
[
1027,
24,
948
]
],
[
[
1171,
63,
1512
],
[
1512,
... | [
[
[
"Meloxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Potassium gluconate"
]
],
[
[
"Meloxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
... | Meloxicam may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Potassium gluconate
Meloxicam (Compound) resembles Piroxicam (Compound) and Piroxicam may cause a moderate interaction that co... |
DB00480 | DB08870 | 1,668 | 850 | [
"DDInter1035",
"DDInter228"
] | Lenalidomide | Brentuximab vedotin | Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties. It is a 4-amino-glutamyl analogue of [thalidomide] and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms. However, lenali... | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Moderate | 1 | [
[
[
1668,
24,
850
]
],
[
[
1668,
25,
788
],
[
788,
24,
850
]
],
[
[
1668,
24,
496
],
[
496,
63,
850
]
],
[
[
1668,
24,
267
],
[
267,
... | [
[
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Lenalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pitavastatin"
],
[
... | Lenalidomide may lead to a major life threatening interaction when taken with Pitavastatin and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine... |
DB00687 | DB11827 | 870 | 433 | [
"DDInter747",
"DDInter669"
] | Fludrocortisone | Ertugliflozin | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
870,
24,
433
]
],
[
[
870,
1,
1103
],
[
1103,
23,
433
]
],
[
[
870,
25,
646
],
[
646,
24,
433
]
],
[
[
870,
63,
1020
],
[
1020,
... | [
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Fludrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Amcinonide"
],
[
"Amcinonide",
"{u} may ca... | Fludrocortisone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Ertugliflozin
Fludrocortisone may lead to a major life threatening interaction when taken with Cinoxacin and Cinoxacin may cause a moderate interaction that could exace... |
DB01229 | DB06717 | 973 | 875 | [
"DDInter1377",
"DDInter778"
] | Paclitaxel | Fosaprepitant | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. | Moderate | 1 | [
[
[
973,
24,
875
]
],
[
[
973,
63,
723
],
[
723,
1,
875
]
],
[
[
973,
21,
29340
],
[
29340,
60,
875
]
],
[
[
973,
63,
1101
],
[
1101,
... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[... | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant (Compound) resembles Fosaprepitant (Compound)
Paclitaxel (Compound) causes Stevens-Johnson syndrome (Side Effect) and Stevens-Johnson syndrome (Side Effect) is caused by Fosaprepitant (Compound)
Paclitax... |
DB00627 | DB11827 | 265 | 433 | [
"DDInter1286",
"DDInter669"
] | Niacin | Ertugliflozin | Niacin is a B vitamin used to treat vitamin deficiencies as well as hyperlipidemia, dyslipidemia, hypertriglyceridemia, and to reduce the risk of myocardial infarctions.[L7550,L7553,L7556,L7559,L7562,L7565] | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
265,
24,
433
]
],
[
[
265,
24,
959
],
[
959,
24,
433
]
],
[
[
265,
63,
1560
],
[
1560,
24,
433
]
],
[
[
265,
24,
959
],
[
959,
6... | [
[
[
"Niacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Niacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"G... | Niacin may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Niacin may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargas... |
DB01155 | DB01211 | 872 | 609 | [
"DDInter813",
"DDInter393"
] | Gemifloxacin | Clarithromycin | Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase... | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Moderate | 1 | [
[
[
872,
24,
609
]
],
[
[
872,
21,
28759
],
[
28759,
60,
609
]
],
[
[
872,
63,
600
],
[
600,
23,
609
]
],
[
[
872,
62,
752
],
[
752,
... | [
[
[
"Gemifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Gemifloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Connective tissue disorder"
],
[
"Connective tissue d... | Gemifloxacin (Compound) causes Connective tissue disorder (Side Effect) and Connective tissue disorder (Side Effect) is caused by Clarithromycin (Compound)
Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a minor interaction that can limi... |
DB00356 | DB01097 | 1,315 | 1,377 | [
"DDInter366",
"DDInter1033"
] | Chlorzoxazone | Leflunomide | A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202) | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Major | 2 | [
[
[
1315,
25,
1377
]
],
[
[
1315,
6,
7950
],
[
7950,
45,
1377
]
],
[
[
1315,
21,
28701
],
[
28701,
60,
1377
]
],
[
[
1315,
24,
1532
],
[
1... | [
[
[
"Chlorzoxazone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Chlorzoxazone",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"... | Chlorzoxazone (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Leflunomide (Compound)
Chlorzoxazone (Compound) causes Discomfort (Side Effect) and Discomfort (Side Effect) is caused by Leflunomide (Compound)
Chlorzoxazone may cause a moderate interaction that could exacerbate diseases when taken with Ifosfa... |
DB01035 | DB12332 | 1,401 | 1,619 | [
"DDInter1524",
"DDInter1626"
] | Procainamide | Rucaparib | A derivative of procaine with less CNS action. | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Major | 2 | [
[
[
1401,
25,
1619
]
],
[
[
1401,
62,
112
],
[
112,
23,
1619
]
],
[
[
1401,
24,
259
],
[
259,
24,
1619
]
],
[
[
1401,
25,
1662
],
[
1662,
... | [
[
[
"Procainamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
]
],
[
[
"Procainamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metron... | Procainamide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Procainamide may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and R... |
DB00072 | DB05273 | 550 | 507 | [
"DDInter1846",
"DDInter1638"
] | Trastuzumab | Samarium (153Sm) lexidronam | Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). It is used as a treatment of human epidermal growth ... | Samarium Sm 153 lexidronam is a radioactive medication used to treat pain caused by cancer that has spread to the bone. It is a radiopharmaceutical. Radiopharmaceuticals are radioactive agents that may be used to diagnose some diseases by studying the function of the body's organs or to treat certain diseases.Samarium ... | Major | 2 | [
[
[
550,
25,
507
]
],
[
[
550,
24,
248
],
[
248,
24,
507
]
],
[
[
550,
24,
270
],
[
270,
63,
507
]
],
[
[
550,
25,
77
],
[
77,
25,
... | [
[
[
"Trastuzumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Trastuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
],
... | Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir and Valganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Samarium (153Sm) lexidronam
Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken... |
DB01328 | DB09268 | 1,323 | 1,662 | [
"DDInter321",
"DDInter1464"
] | Cefonicid | Picosulfuric acid | A second-generation cephalosporin administered intravenously or intramuscularly. Its bactericidal action results from inhibition of cell wall synthesis. It is used for urinary tract infections, lower respiratory tract infections, and soft tissue and bone infections. | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
1323,
24,
1662
]
],
[
[
1323,
63,
597
],
[
597,
24,
1662
]
],
[
[
1323,
40,
1124
],
[
1124,
24,
1662
]
],
[
[
1323,
1,
1402
],
[
1402,... | [
[
[
"Cefonicid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Cefonicid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
]... | Cefonicid may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Cefonicid (Compound) resembles Cefamandole (Compound) and Cefamandole may cause a moderate inter... |
DB00938 | DB12332 | 455 | 1,619 | [
"DDInter1635",
"DDInter1626"
] | Salmeterol | Rucaparib | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
455,
24,
1619
]
],
[
[
455,
24,
222
],
[
222,
23,
1619
]
],
[
[
455,
63,
307
],
[
307,
23,
1619
]
],
[
[
455,
63,
87
],
[
87,
24... | [
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafini... |
DB00501 | DB09481 | 752 | 460 | [
"DDInter380",
"DDInter1113"
] | Cimetidine | Magnesium carbonate | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Magnesium carbonate, also known as magnesite, is a common over the counter remedy for heartburn and upset stomach caused by overproduction of acid in the stomach [FDA Label]. | Minor | 0 | [
[
[
752,
23,
460
]
],
[
[
752,
62,
1252
],
[
1252,
23,
460
]
],
[
[
752,
24,
1382
],
[
1382,
23,
460
]
],
[
[
752,
63,
461
],
[
461,
... | [
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Digoxin"
],
[
... | Cimetidine may cause a minor interaction that can limit clinical effects when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Midazolam and Midazola... |
DB00197 | DB12825 | 1,324 | 1,375 | [
"DDInter1881",
"DDInter1032"
] | Troglitazone | Lefamulin | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August... | Moderate | 1 | [
[
[
1324,
24,
1375
]
],
[
[
1324,
24,
159
],
[
159,
63,
1375
]
],
[
[
1324,
63,
966
],
[
966,
24,
1375
]
],
[
[
1324,
24,
1532
],
[
1532,
... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Octreotide a... |
DB10429 | DB11714 | 200 | 1,316 | [
"DDInter282",
"DDInter610"
] | Candida albicans | Durvalumab | Candida albicans is a fungus which can provoke allergic reactions. Candida albicans is used in allergenic testing. | Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote... | Moderate | 1 | [
[
[
200,
24,
1316
]
],
[
[
200,
63,
167
],
[
167,
24,
1316
]
],
[
[
200,
24,
270
],
[
270,
63,
1316
]
],
[
[
200,
63,
976
],
[
976,
... | [
[
[
"Candida albicans",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Durvalumab"
]
],
[
[
"Candida albicans",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"... | Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Durvalumab
Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with O... |
DB06674 | DB11988 | 908 | 270 | [
"DDInter837",
"DDInter1321"
] | Golimumab | Ocrelizumab | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-human... | Major | 2 | [
[
[
908,
25,
270
]
],
[
[
908,
23,
1193
],
[
1193,
23,
270
]
],
[
[
908,
62,
1461
],
[
1461,
23,
270
]
],
[
[
908,
25,
1060
],
[
1060,
... | [
[
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Golimumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gluc... | Golimumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Ocrelizumab
Golimumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitami... |
DB00220 | DB06697 | 798 | 436 | [
"DDInter1276",
"DDInter121"
] | Nelfinavir | Artemether | Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. | Artemether is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with lumefantrine for improved efficacy. This combination therapy exerts its effects against the erythrocytic stages of <i>Plasmodium spp.</i> and may be used to treat infections caused by <i>P. falciparum</... | Major | 2 | [
[
[
798,
25,
436
]
],
[
[
798,
6,
12523
],
[
12523,
45,
436
]
],
[
[
798,
24,
353
],
[
353,
24,
436
]
],
[
[
798,
25,
283
],
[
283,
... | [
[
[
"Nelfinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Artemether"
]
],
[
[
"Nelfinavir",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Artemet... | Nelfinavir (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Artemether (Compound)
Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin and Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Artemether
Nelfinavir may... |
DB00762 | DB12141 | 613 | 971 | [
"DDInter973",
"DDInter817"
] | Irinotecan | Gilteritinib | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cel... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
613,
24,
971
]
],
[
[
613,
24,
466
],
[
466,
62,
971
]
],
[
[
613,
24,
1097
],
[
1097,
24,
971
]
],
[
[
613,
63,
1023
],
[
1023,
... | [
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
... | Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan and La... |
DB00400 | DB01174 | 353 | 697 | [
"DDInter843",
"DDInter1442"
] | Griseofulvin | Phenobarbital | An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections. | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Moderate | 1 | [
[
[
353,
24,
697
]
],
[
[
353,
24,
759
],
[
759,
1,
697
]
],
[
[
353,
24,
536
],
[
536,
40,
697
]
],
[
[
353,
63,
1023
],
[
1023,
1,... | [
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
]
],
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
],
... | Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Primidone and Primidone (Compound) resembles Phenobarbital (Compound)
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital and Secobarbital (Compound) resembles Phenobarbital... |
DB00683 | DB09074 | 1,382 | 1,362 | [
"DDInter1212",
"DDInter1327"
] | Midazolam | Olaparib | Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called _benzodiazepines_. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazola... | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Moderate | 1 | [
[
[
1382,
24,
1362
]
],
[
[
1382,
24,
1683
],
[
1683,
24,
1362
]
],
[
[
1382,
24,
1619
],
[
1619,
63,
1362
]
],
[
[
1382,
63,
58
],
[
58,
... | [
[
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
... | Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib... |
DB06282 | DB14881 | 516 | 180 | [
"DDInter1053",
"DDInter1329"
] | Levocetirizine | Oliceridine | Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine. Levocetirizine was granted FDA approval in 1995. | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid recepto... | Moderate | 1 | [
[
[
516,
24,
180
]
],
[
[
516,
63,
401
],
[
401,
24,
180
]
],
[
[
516,
24,
407
],
[
407,
24,
180
]
],
[
[
516,
63,
593
],
[
593,
25,... | [
[
[
"Levocetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Levocetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
... | Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Opium an... |
DB01261 | DB08899 | 170 | 129 | [
"DDInter1679",
"DDInter649"
] | Sitagliptin | Enzalutamide | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improv... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
170,
24,
129
]
],
[
[
170,
6,
8374
],
[
8374,
45,
129
]
],
[
[
170,
7,
5774
],
[
5774,
46,
129
]
],
[
[
170,
21,
29377
],
[
29377,
... | [
[
[
"Sitagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Sitagliptin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compoun... | Sitagliptin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Sitagliptin (Compound) upregulates SELL (Gene) and SELL (Gene) is upregulated by Enzalutamide (Compound)
Sitagliptin (Compound) causes Musculoskeletal pain (Side Effect) and Musculoskeletal pain (Side Effect) is caused by E... |
DB00555 | DB00835 | 706 | 100 | [
"DDInter1020",
"DDInter245"
] | Lamotrigine | Brompheniramine | Lamotrigine is an antiepileptic drug belonging in the phenyltriazine class. It is used in the treatment of both epilepsy and as a mood stabilizer in bipolar disorder. Lamotrigine is the first medication since lithium granted Food and Drug Administration (FDA) approval for the maintenance treatment of bipolar type I. It... | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Moderate | 1 | [
[
[
706,
24,
100
]
],
[
[
706,
24,
832
],
[
832,
24,
100
]
],
[
[
706,
63,
128
],
[
128,
24,
100
]
],
[
[
706,
24,
649
],
[
649,
63,... | [
[
[
"Lamotrigine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Lamotrigine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
... | Lamotrigine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Lamotrigine may cause a moderate interaction that could exacerbate diseases when taken with Dexbro... |
DB11834 | DB14783 | 1,303 | 287 | [
"DDInter849",
"DDInter574"
] | Guselkumab | Diroximel fumarate | Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation. In clinical trials, guselkumab demonstrat... | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting ... | Moderate | 1 | [
[
[
1303,
24,
287
]
],
[
[
1303,
63,
599
],
[
599,
24,
287
]
],
[
[
1303,
24,
270
],
[
270,
24,
287
]
],
[
[
1303,
64,
1510
],
[
1510,
... | [
[
[
"Guselkumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Guselkumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],... | Guselkumab may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Guselkumab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab... |
DB00424 | DB01359 | 19 | 729 | [
"DDInter896",
"DDInter1417"
] | Hyoscyamine | Penbutolol | Hyoscyamine is a tropane alkaloid and the levo-isomer of [atropine]. It is commonly extracted from plants in the _Solanaceae_ or nightshade family. Research into the action of hyoscyamine in published literature dates back to 1826. Hyoscyamine is used for a wide variety of treatments and therapeutics due to its antimus... | Penbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker. Penbutolol can act as a partial agonist at beta adrenergic receptors, since it is a sympathomimetric drug. Penbutolol also demonstrates high... | Moderate | 1 | [
[
[
19,
24,
729
]
],
[
[
19,
63,
461
],
[
461,
1,
729
]
],
[
[
19,
24,
699
],
[
699,
40,
729
]
],
[
[
19,
21,
28698
],
[
28698,
60,
... | [
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Penbutolol"
]
],
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
],
[
... | Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol (Compound) resembles Penbutolol (Compound)
Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Nadolol and Nadolol (Compound) resembles Penbutolol (Compound)
Hyoscyamin... |
DB01181 | DB09133 | 1,532 | 1,527 | [
"DDInter906",
"DDInter965"
] | Ifosfamide | Iothalamic acid | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Iothalamic acid is an iodine containing organic anion used as a diagnostic contrast agent. | Major | 2 | [
[
[
1532,
25,
1527
]
],
[
[
1532,
24,
242
],
[
242,
63,
1527
]
],
[
[
1532,
63,
1648
],
[
1648,
24,
1527
]
],
[
[
1532,
63,
589
],
[
589,
... | [
[
[
"Ifosfamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iothalamic acid"
]
],
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
],
[
"Remde... | Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir and Remdesivir may cause a moderate interaction that could exacerbate diseases when taken with Iothalamic acid
Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and ... |
DB00687 | DB09473 | 870 | 884 | [
"DDInter747",
"DDInter918"
] | Fludrocortisone | Indium In-111 oxyquinoline | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Indium In 111 oxyquinoline (oxine) is a diagnostic radiopharmaceutical intended for radiolabeling of autologous leukocytes. It is composed of a 3:1 saturated complex of In-111 isotope and oxyquinoline. Indium-111 decays by isomeric transition and electron capture to cadmium-111, emitting a gamma ray that can be detecte... | Moderate | 1 | [
[
[
870,
24,
884
]
],
[
[
870,
1,
891
],
[
891,
24,
884
]
],
[
[
870,
24,
609
],
[
609,
24,
884
]
],
[
[
870,
1,
891
],
[
891,
1,
... | [
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indium In-111 oxyquinoline"
]
],
[
[
"Fludrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisolone"
],
[
"Prednisolone",
... | Fludrocortisone (Compound) resembles Prednisolone (Compound) and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Indium In-111 oxyquinoline
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may c... |
DB01157 | DB10989 | 304 | 496 | [
"DDInter1875",
"DDInter858"
] | Trimetrexate | Hepatitis A Vaccine | A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against pneumocystis pneumonia in AIDS patients. Myelosuppression is its dose-limiting toxic effect. | Hepatitis A viral infection can lead to significant morbidity and mortality, with signs and symptoms that include anorexia, nausea, vomiting, and liver failure. Known by several trade names, such as Havrix and Twinrix, the Hepatitis A vaccine has been formulated for immunization against hepatitis A virus (HAV) infectio... | Moderate | 1 | [
[
[
304,
24,
496
]
],
[
[
304,
24,
4
],
[
4,
24,
496
]
],
[
[
304,
24,
738
],
[
738,
63,
496
]
],
[
[
304,
25,
976
],
[
976,
24,
... | [
[
[
"Trimetrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Trimetrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine me... | Trimetrexate may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Trimetrexate may cause a moderate interaction that could exacerbate dis... |
DB00843 | DB01211 | 479 | 609 | [
"DDInter583",
"DDInter393"
] | Donepezil | Clarithromycin | In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and i... | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Minor | 0 | [
[
[
479,
23,
609
]
],
[
[
479,
6,
8374
],
[
8374,
45,
609
]
],
[
[
479,
18,
2183
],
[
2183,
57,
609
]
],
[
[
479,
21,
28662
],
[
28662,
... | [
[
[
"Donepezil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clarithromycin"
]
],
[
[
"Donepezil",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Donepezil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Clarithromycin (Compound)
Donepezil (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Clarithromycin (Compound)
Donepezil (Compound) causes Tremor (Side Effect) and Tremor (Side Effect) is caused by Clarithromycin (Compound)... |
DB08903 | DB09268 | 996 | 1,662 | [
"DDInter170",
"DDInter1464"
] | Bedaquiline | Picosulfuric acid | Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affe... | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Major | 2 | [
[
[
996,
25,
1662
]
],
[
[
996,
25,
484
],
[
484,
63,
1662
]
],
[
[
996,
64,
1618
],
[
1618,
24,
1662
]
],
[
[
996,
63,
912
],
[
912,
... | [
[
[
"Bedaquiline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Bedaquiline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
... | Bedaquiline may lead to a major life threatening interaction when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Bedaquiline may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause ... |
DB00224 | DB12332 | 215 | 1,619 | [
"DDInter917",
"DDInter1626"
] | Indinavir | Rucaparib | A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem] | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
215,
24,
1619
]
],
[
[
215,
23,
222
],
[
222,
23,
1619
]
],
[
[
215,
25,
1135
],
[
1135,
23,
1619
]
],
[
[
215,
24,
309
],
[
309,
... | [
[
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Indinavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
[
... | Indinavir may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Indinavir may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor... |
DB00304 | DB06335 | 1,657 | 761 | [
"DDInter508",
"DDInter1646"
] | Desogestrel | Saxagliptin | Desogestrel, a prodrug, is a third generation progestogen and hence, a member of the gonane family which was largely used in Europe before being approved in the US and Canada. It was firstly generated from a study that showed that 11-beta and 11-alkylidene substituent in nortestosterone can enhance the biological activ... | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Moderate | 1 | [
[
[
1657,
24,
761
]
],
[
[
1657,
21,
28722
],
[
28722,
60,
761
]
],
[
[
1657,
24,
1296
],
[
1296,
63,
761
]
],
[
[
1657,
1,
1336
],
[
1336... | [
[
[
"Desogestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Desogestrel",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused ... | Desogestrel (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Saxagliptin (Compound)
Desogestrel may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00363 | DB08826 | 695 | 1,292 | [
"DDInter419",
"DDInter489"
] | Clozapine | Deferiprone | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA ap... | Major | 2 | [
[
[
695,
25,
1292
]
],
[
[
695,
24,
603
],
[
603,
63,
1292
]
],
[
[
695,
64,
482
],
[
482,
25,
1292
]
],
[
[
695,
25,
1426
],
[
1426,
... | [
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
]
],
[
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
],
[
"Magn... | Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate and Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Deferiprone
Clozapine may lead to a major life threatening interaction when taken with Tioguanine and Tioguani... |
DB00308 | DB00526 | 347 | 1,555 | [
"DDInter901",
"DDInter1355"
] | Ibutilide | Oxaliplatin | Ibutilide is a Class III antiarrhythmic agent available in intravenous formulations. It is indicated for the conversion of acute atrial flutter and recent onset atrial fibrillation to normal sinus rhythm (NSR). | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Major | 2 | [
[
[
347,
25,
1555
]
],
[
[
347,
25,
79
],
[
79,
24,
1555
]
],
[
[
347,
25,
1213
],
[
1213,
63,
1555
]
],
[
[
347,
64,
618
],
[
618,
... | [
[
[
"Ibutilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxaliplatin"
]
],
[
[
"Ibutilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sorafenib"
],
[
"Sorafenib",
"{u} may ... | Ibutilide may lead to a major life threatening interaction when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Ibutilide may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interacti... |
DB00374 | DB00564 | 1,061 | 1,236 | [
"DDInter1852",
"DDInter293"
] | Treprostinil | Carbamazepine | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated w... | Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbam... | Moderate | 1 | [
[
[
1061,
24,
1236
]
],
[
[
1061,
63,
362
],
[
362,
1,
1236
]
],
[
[
1061,
24,
97
],
[
97,
1,
1236
]
],
[
[
1061,
6,
6017
],
[
6017,
... | [
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbamazepine"
]
],
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
... | Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Carbamazepine (Compound)
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Oxaprozin and Oxaprozin (Compound) resembles Carbamazepine (Comp... |
DB00006 | DB00078 | 942 | 1,172 | [
"DDInter217",
"DDInter898"
] | Bivalirudin | Ibritumomab tiuxetan | Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important t... | Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light... | Major | 2 | [
[
[
942,
25,
1172
]
],
[
[
942,
23,
539
],
[
539,
62,
1172
]
],
[
[
942,
24,
578
],
[
578,
63,
1172
]
],
[
[
942,
25,
707
],
[
707,
... | [
[
[
"Bivalirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ibritumomab tiuxetan"
]
],
[
[
"Bivalirudin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
],
[
"Ca... | Bivalirudin may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Ibritumomab tiuxetan
Bivalirudin may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ti... |
DB00853 | DB11943 | 1,686 | 255 | [
"DDInter1762",
"DDInter495"
] | Temozolomide | Delafloxacin | Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alky... | Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, and Community Acquired Pneumonia, among others. It was approved in June 2017 under the trade name Baxdela for use in t... | Minor | 0 | [
[
[
1686,
23,
255
]
],
[
[
1686,
63,
372
],
[
372,
23,
255
]
],
[
[
1686,
24,
995
],
[
995,
23,
255
]
],
[
[
1686,
63,
663
],
[
663,
... | [
[
[
"Temozolomide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Delafloxacin"
]
],
[
[
"Temozolomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
],
... | Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may cause a minor interaction that can limit clinical effects when taken with Delafloxacin
Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyurea and... |
DB00241 | DB01284 | 288 | 1,042 | [
"DDInter257",
"DDInter1782"
] | Butalbital | Tetracosactide | Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. It is a short-to-intermediate acting member of barbiturates that exhibit muscle-relaxing and anti-anxiety properties that produce central nervou... | Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticoste... | Moderate | 1 | [
[
[
288,
24,
1042
]
],
[
[
288,
40,
1023
],
[
1023,
24,
1042
]
],
[
[
288,
24,
761
],
[
761,
63,
1042
]
],
[
[
288,
25,
126
],
[
126,
... | [
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Butalbital",
"{u} (Compound) resembles {v} (Compound)",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} may cause... | Butalbital (Compound) resembles Pentobarbital (Compound) and Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a moderate interactio... |
DB00289 | DB00526 | 847 | 1,555 | [
"DDInter132",
"DDInter1355"
] | Atomoxetine | Oxaliplatin | Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve develop... | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Moderate | 1 | [
[
[
847,
24,
1555
]
],
[
[
847,
24,
79
],
[
79,
24,
1555
]
],
[
[
847,
24,
1297
],
[
1297,
63,
1555
]
],
[
[
847,
63,
618
],
[
618,
... | [
[
[
"Atomoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
]
],
[
[
"Atomoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
[
... | Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osi... |
DB01185 | DB09564 | 155 | 1,296 | [
"DDInter759",
"DDInter930"
] | Fluoxymesterone | Insulin degludec | An anabolic steroid that has been used in the treatment of male hypogonadism, delayed puberty in males, and in the treatment of breast neoplasms in women. | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
155,
24,
1296
]
],
[
[
155,
40,
1103
],
[
1103,
23,
1296
]
],
[
[
155,
63,
1411
],
[
1411,
24,
1296
]
],
[
[
155,
1,
303
],
[
303,
... | [
[
[
"Fluoxymesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Fluoxymesterone",
"{u} (Compound) resembles {v} (Compound)",
"Amcinonide"
],
[
"Amcinonide",
"{u} may... | Fluoxymesterone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Insulin degludec
Fluoxymesterone may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate intera... |
DB00261 | DB00539 | 702 | 11 | [
"DDInter93",
"DDInter1837"
] | Anagrelide | Toremifene | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | Major | 2 | [
[
[
702,
25,
11
]
],
[
[
702,
6,
7950
],
[
7950,
45,
11
]
],
[
[
702,
18,
11048
],
[
11048,
46,
11
]
],
[
[
702,
7,
3218
],
[
3218,
... | [
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
]
],
[
[
"Anagrelide",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Toremif... | Anagrelide (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Toremifene (Compound)
Anagrelide (Compound) downregulates VAT1 (Gene) and VAT1 (Gene) is upregulated by Toremifene (Compound)
Anagrelide (Compound) upregulates IKBKE (Gene) and IKBKE (Gene) is upregulated by Toremifene (Compound)
Anagrelide (Compou... |
DB00804 | DB00915 | 1,507 | 1,170 | [
"DDInter543",
"DDInter60"
] | Dicyclomine | Amantadine | Dicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder and irritable bowel syndrome.[A6556,A182555,A234659,L7967] Though it is commonly prescribed, its recommendation may h... | An antiviral that is used in the prophylactic or symptomatic treatment of influenza A. It is also used as an antiparkinsonian agent, to treat extrapyramidal reactions, and for postherpetic neuralgia. The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesi... | Moderate | 1 | [
[
[
1507,
24,
1170
]
],
[
[
1507,
21,
29648
],
[
29648,
60,
1170
]
],
[
[
1507,
63,
1219
],
[
1219,
24,
1170
]
],
[
[
1507,
24,
1376
],
[
... | [
[
[
"Dicyclomine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amantadine"
]
],
[
[
"Dicyclomine",
"{u} (Compound) causes {v} (Side Effect)",
"Disorientation"
],
[
"Disorientation",
"{u} (Side Eff... | Dicyclomine (Compound) causes Disorientation (Side Effect) and Disorientation (Side Effect) is caused by Amantadine (Compound)
Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Azatadine and Azatadine may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB00584 | DB08880 | 610 | 1,510 | [
"DDInter638",
"DDInter1771"
] | Enalapril | Teriflunomide | Enalapril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor drug class that works on the renin-angiotensin-aldosterone system, which is responsible for the regulation of blood pressure and fluid and electrolyte homeostasis. Enalapril is an orally-active and long-acting nonsulphydryl antihypert... | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
610,
25,
1510
]
],
[
[
610,
24,
1144
],
[
1144,
24,
1510
]
],
[
[
610,
24,
1450
],
[
1450,
63,
1510
]
],
[
[
610,
63,
1061
],
[
1061,
... | [
[
[
"Enalapril",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Enalapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[
"Nateglin... | Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and ... |
DB00031 | DB01191 | 20 | 1,039 | [
"DDInter1764",
"DDInter518"
] | Tenecteplase | Dexfenfluramine | Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at ... | Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was with... | Moderate | 1 | [
[
[
20,
24,
1039
]
],
[
[
20,
25,
1046
],
[
1046,
63,
1039
]
],
[
[
20,
24,
578
],
[
578,
63,
1039
]
],
[
[
20,
24,
935
],
[
935,
24... | [
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexfenfluramine"
]
],
[
[
"Tenecteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Caplacizumab"
],
[
... | Tenecteplase may lead to a major life threatening interaction when taken with Caplacizumab and Caplacizumab may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine
Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrel... |
DB00497 | DB09052 | 828 | 250 | [
"DDInter1366",
"DDInter220"
] | Oxycodone | Blinatumomab | Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The f... | Blinatumomab is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through a short peptide linker.[A254836,L44311] CD3 is an antigen expressed on the surface of T-cells, while CD19 is mostl... | Moderate | 1 | [
[
[
828,
24,
250
]
],
[
[
828,
24,
1662
],
[
1662,
63,
250
]
],
[
[
828,
63,
1503
],
[
1503,
24,
250
]
],
[
[
828,
25,
267
],
[
267,
... | [
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Blinatumomab"
]
],
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
],
... | Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab
Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Lindane... |
DB01193 | DB06663 | 819 | 1,154 | [
"DDInter12",
"DDInter1398"
] | Acebutolol | Pasireotide | A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action. | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Moderate | 1 | [
[
[
819,
24,
1154
]
],
[
[
819,
63,
966
],
[
966,
40,
1154
]
],
[
[
819,
21,
28900
],
[
28900,
60,
1154
]
],
[
[
819,
40,
88
],
[
88,
... | [
[
[
"Acebutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
]
],
[
[
"Acebutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Octreotide"
],
[
... | Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Octreotide and Octreotide (Compound) resembles Pasireotide (Compound)
Acebutolol (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Pasireotide (Compound)
Acebutolol (Compound) resembles ... |
DB00514 | DB00777 | 506 | 146 | [
"DDInter527",
"DDInter1537"
] | Dextromethorphan | Propiomazine | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | Propiomazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. Future uses may include the treatment of obsessive-compulsive disorder and severe behavioral disorders in autism. Struct... | Moderate | 1 | [
[
[
506,
24,
146
]
],
[
[
506,
63,
508
],
[
508,
1,
146
]
],
[
[
506,
24,
401
],
[
401,
63,
146
]
],
[
[
506,
24,
1178
],
[
1178,
1,... | [
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
]
],
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
... | Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Propiomazine (Compound)
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate intera... |
DB00748 | DB08815 | 662 | 154 | [
"DDInter297",
"DDInter1104"
] | Carbinoxamine | Lurasidone | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. | Moderate | 1 | [
[
[
662,
24,
154
]
],
[
[
662,
6,
8374
],
[
8374,
45,
154
]
],
[
[
662,
21,
29118
],
[
29118,
60,
154
]
],
[
[
662,
24,
1532
],
[
1532,
... | [
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurasidone"
]
],
[
[
"Carbinoxamine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compo... | Carbinoxamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lurasidone (Compound)
Carbinoxamine (Compound) causes Tachycardia (Side Effect) and Tachycardia (Side Effect) is caused by Lurasidone (Compound)
Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfa... |
DB05679 | DB11952 | 1,683 | 800 | [
"DDInter1907",
"DDInter612"
] | Ustekinumab | Duvelisib | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed tha... | Moderate | 1 | [
[
[
1683,
24,
800
]
],
[
[
1683,
24,
310
],
[
310,
24,
800
]
],
[
[
1683,
63,
467
],
[
467,
24,
800
]
],
[
[
1683,
24,
1476
],
[
1476,
... | [
[
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
]
],
[
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
... | Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Si... |
DB00457 | DB11130 | 1,205 | 407 | [
"DDInter1511",
"DDInter1344"
] | Prazosin | Opium | Prazosin is a drug used to treat hypertension. Prazosin is marketed by _Pfizer_ and was initially approved by the FDA in 1988. It belongs to the class of drugs known as alpha-1 antagonists. Recently, many studies have evaluated the benefits of this drug in controlling the symptoms of post-traumatic stress disorder (PTS... | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papave... | Moderate | 1 | [
[
[
1205,
24,
407
]
],
[
[
1205,
40,
1433
],
[
1433,
24,
407
]
],
[
[
1205,
24,
104
],
[
104,
24,
407
]
],
[
[
1205,
63,
1648
],
[
1648,
... | [
[
[
"Prazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Prazosin",
"{u} (Compound) resembles {v} (Compound)",
"Doxazosin"
],
[
"Doxazosin",
"{u} may cause a moderate interacti... | Prazosin (Compound) resembles Doxazosin (Compound) and Doxazosin may cause a moderate interaction that could exacerbate diseases when taken with Opium
Prazosin may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacer... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.